Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 May 28;10(5):e0127628. doi: 10.1371/journal.pone.0127628

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.

PMC Copyright notice

Fig 3 — Female mice under anesthesia, received intravesical instillation of a PAR1 or PAR4 activating peptide (AP) or a respective scrambled peptide (Control Pep: RLLFT-NH2 for PAR1; YAPGKF-NH2 for PAR4) for one hour before harvesting bladders. Panels (A, B, D, E) show MIF immunofluorescent labeling in representative bladders. White arrows point to intraluminal surface of the urothelia. MIF immunofluorescent labeling localized to urothelium (A, D) and a decrease in urothelial MIF immunofluorescence was observed after PAR1-AP (B) or PAR-4-AP (E) treatment when compared to control peptide-treated groups (A, D). Densitometry showed that average urothelial MIF immunofluorescence (N = 6 per group) significantly decreased after intravesical PAR1- (C) or PAR4-AP (F) treatment when compared to respective control groups (* p ≤ 0.05).